Category Archives: Embryonic Stem Cells


In Cells and Whole Organisms, Repair Mechanisms Imply Foresight, Not Evolution – Discovery Institute

Photo credit: JC Gellidon via Unsplash.

Cells and organisms come pre-equipped with repair mechanisms. It takes foresight to make complex tools and procedures that can restore the functions of other tools. A blind process like evolution can only see the immediate present; it would be unconcerned about what happens next. Repair implies something worth saving. The more delicate the product, the more elaborate the maintenance. Live is both worth saving and it is delicate. Predictably, the persistence of life presupposes elaborate repair systems are at work. The following research findings show just how complex some of these repair mechanisms are.

Here is a kind of repair strategy that truly would require foresight. A skilled orthopedic surgeon can look at a broken bone and, through years of training, know that before setting it, he needs to make the break worse. In a compound fracture, for instance, bending the bone farther can allow splintered bones to be put back together. Additionally, assistants in the operating room can apply materials or medicines while the surgeon holds the fracture open. Something like that happens in the nucleus or our cells, scientists found at Lawrence Berkeley National Lab. Sometimes, when something is broken, the first step to fixing it is to break it even more. A molecular machine named XPG could be dubbed an orthogenic surgeon (ortho- meaning straight).

We saw that XPG makes a beeline for discontinuous DNA places where the hydrogen bonds between bases on each strand of the helix have been disrupted and then it very dramatically bends the strand at that exact location, breaking the interface that connects bases stacked on top of each other, said Susan Tsutakawa, a structural biologist in the Biosciences Area at Lawrence Berkeley National Laboratory (Berkeley Lab) and first author on the work, published this month in PNAS. The bending activity adds to an already impressive arsenal, as XPG was first identified as a DNA chopping enzyme, responsible for cutting out nucleotide bases with chemical and UV radiation damage. [Emphasis added.]

Natural selection would never do this. First of all, how would XPG recognize a problem that doesnt affect it directly, and how would it know to make a beeline for something elses problem? Then, if by some accident of chance it bent the DNA strand, how would it know how to perform the next surgical step? XPG would be out of a job, rushing toward discontinuous DNA like a blind driver on a demolition derby, breaking genes here and there, killing the organism by a thousand cuts. Instead, look what it does:

An unexpected finding from our imaging data is that the flexible parts of the protein which were previously impossible to examine have the ability to recognize perturbations associated with many different types of DNA damage, said co-author Priscilla Cooper, a biochemist senior scientist in the Biosciences Area. XPG then uses its sculpting properties to bend the DNA in order to recruit and load into place the proteins that can fix that type of damage.

The scientists call this a protein with many jobs that is more like a master sculptor than a demolition crew. Without XPG, a person can incur devastating symptoms of diseases. Some of these fatal syndromes caused by faulty XPG are described in the press release. Often single amino acid substitutions can destabilize the entire protein, they say. If that doesnt clinch the case for design, consider also that the Lawrence Berkeley team found that XPG cooperates with other repair machines like BRCA1 and BRCA2. An entire operating-room team has the foresight to perform orthogenic surgery on DNA. The Darwin-free paper is published in PNAS.1

The brain is busier than a city all the time, even in sleep. Amidst all the clamor, one issue cannot be overlooked: how to dispose of dead cells. A recent article at Evolution News described how the cellular morgue takes care of the problem. In the brain, it is even more vital to quickly eliminate dead cells. A team at Yale School of Medicine heard music inside the skull: they found that astrocytes and microglia perform orchestrated roles and respect phagocytic territories during neuronal corpse removal in the brain. Each player knows its part.

Cell death is prevalent throughout life; however, the coordinated interactions and roles of phagocytes during corpse removal in the live brain are poorly understood. We developed photochemical and viral methodologies to induce death in single cells and combined this with intravital optical imaging. This approach allowed us to track multicellular phagocytic interactions with precise spatiotemporal resolution. Astrocytes and microglia engaged with dying neurons in an orchestrated and synchronized fashion. Each glial cell played specialized roles: Astrocyte processes rapidly polarized and engulfed numerous small dendritic apoptotic bodies, while microglia migrated and engulfed the soma and apical dendrites. The relative involvement and phagocytic specialization of each glial cell was plastic and controlled by the receptor tyrosine kinase Mertk Thus, a precisely orchestrated response and cross-talk between glial cells during corpse removal may be critical for maintaining brain homeostasis.

Their research is published in Science Advances.2 This paper was also Darwin-free except for an opening pinch of incense in the first sentence, Cell death is an evolutionarily conserved and ubiquitous process a useless offering that contributes nothing to the science except to show that evolution was not observed.

Every human life has value, even those with genetic defects (and which human being does not suffer from several?). Whats important to the argument for intelligent design from foresight is how carefully the body practices preventative medicine on the developing embryo. Scientists at Caltech point out,

The first few days of embryonic development are a critical point for determining the failure or success of a pregnancy. Because relatively few cells make up the embryo during this period, the health of each cell is vital to the health of the overall embryo. But often, these young cells have chromosomal aneuploidies meaning, there are too many or too few chromosome copies in the cell. Aneuploid cells lead to the failure of the pregnancy, or cause developmental defects such as Down syndrome later in gestation.

Fortunately, these young embryos perform their own quality control before most genetic abnormalities become established:

Researchers have found that the prevalence of aneuploidy is drastically lower as the embryo grows and develops. Using mouse embryos, scientists from the laboratory of Magdalena Zernicka-Goetz, Caltechs Bren Professor of Biology and Biological Engineering, now show that this is because embryos are able to rid themselves of abnormal cells just before and soon after implantation into the uterus, thereby keeping the whole embryo healthy.

It is remarkable that embryos can do this, says Zernicka-Goetz. It reflects their plasticity that gives them the power to self-repair.

The scientists found a double-protection mechanism. Not only are aneuploidy cells detected and eliminated, but healthy cells are stimulated to proliferate, compensating for the loss of unhealthy cells. The research paper, which also fails to give credit to evolution for this wonderful example of foresight and design, appeared in Nature Communications on June 11.3

Even plants, lacking eyes and brains, know how to repair damage. Plants have a handicap that makes repair more difficult: their repair teams cannot migrate to the site of the injury. Austrian scientists discovered a clever way that a plant can send repair enzymes to the rescue when a stem gets wounded.

Plants are sessile organisms that cannot evade wounding or pathogen attack, and their cells are encapsulated within cell walls, making it impossible to use cell migration for wound healing like animals. Thus, regeneration in plants largely relies on the coordination of targeted cell expansion and oriented cell division. Here we show in the root that the major growth hormone auxin is specifically activated in wound-adjacent cells, regulating cell expansion, cell division rates, and regeneration-involved transcription factor ERF115. These wound responses depend on cell collapse of the eliminated cells presumably perceived by the cell damage-induced changes in cellular pressure. This largely broadens our understanding of how wound responses are coordinated on a cellular level to mediate wound healing and prevent overproliferation.

The research is published in PNAS.4 Its satisfying to say, again, that their paper did not give any credit to evolution. This is one way design wins by default: repeated failures of Darwinists to show up for the game constitutes abdication.

The concept of repair presupposes foresight.5 How would a blind, unguided process recognize a problem? Even if a working plant or animal were granted a hypothetical existence by evolution, the easiest thing for natural selection to do when a problem occurs is to let the organism die. Uncaring selection owes it no further existence. As these examples show (and there are many, many more), life comes equipped with repair teams that are even more complex than expected. It is remarkable that embryos can do this, Caltech scientists said. Yale scientists watched a precisely orchestrated response to cell death in the brain. Lawrence Berkeley scientists did not expect to see a master sculptor in the nucleus already known to have an impressive arsenal of abilities able to surgically straighten DNA before their eyes. These are the emotional responses of people astonished by design beyond their dreams. If they attribute these wonders to evolution, their silence speaks volumes.

Read more from the original source:
In Cells and Whole Organisms, Repair Mechanisms Imply Foresight, Not Evolution - Discovery Institute

Why are scientists trying to manufacture organs in space? – Stuff Magazines

Gravity can be a real downer when you are trying to grow organs.

Thats why experiments in space are so valuable. They have revealed a new perspective into biological sciences, including insights into making human tissues.

Gravity influences cellular behavior by impacting how protein and genes interact inside the cells, creating tissue that ispolarized, a fundamental step for natural organ development. Unfortunately, gravity is against us when we try to reproduce complex three dimensional tissues in the lab for medical transplantation. This is difficult because of the intrinsic limitations of bio-reactors used on Earth.

I am a stem cell biologist and interested on brain health and evolution. My lab studies how the human brain is formed inside the womb and how alterations in this process might have lifelong consequences to human behavior, such as in autism or schizophrenia. Part of that work includes growing brain cells in space.

To build organized tissues in the lab, scientists use scaffolds to provide a surface for cells to attach based on a predetermined rigid shape. For example, an artificial kidney needs a structure, or scaffold, of a certain shape for kidney cells to grow on. Indeed, this strategy helps the tissue to organize in the early stages but creates problems in the long run, such as eventual immune reactions to these synthetic scaffolds or inaccurate structures.

By contrast, in weightless conditions, cells can freely self-organize into their correct three-dimensional structure without the need for a scaffold substrate. By removing gravity from the equation, we researchers might learn new ways of building human tissues, such as cartilage and blood vessels that are scaffold-free, mimicking their natural cellular arrangement in an artificial setting. While this is not exactly what happens in the womb (after all the womb is also subject to gravity), weightless conditions does give us an advantage.

And this is precisely what is happening at the International Space Station.

These experiments help researchers optimize tissue growth for use in basic science, personalized medicine and organ transplantation.

But there are other reasons why we should manufacture organs in space. Long-term space missions create a series of physiological alterations in the body of astronauts. While some of these alterations are reversible with time, others are not, compromising future human spaceflights.

Studying astronauts bodies before and after their mission can reveal what goes wrong on their organs, but provides little insights on the mechanisms responsible for the observed alterations. Thus, growing human tissues in space can complement this type of investigation and reveal ways to counteract it.

Finally, all forms of life that we know about have evolved in the presence of microgravity. Without gravity, our brains might have evolved in a different trajectory, or our livers might not filter liquids as it does on Earth.

By recreating embryonic organ formation in space, we can anticipate how the human body in the womb would develop. There are several research initiatives going on in my lab with human brain organoids at ISS, designed to learn the impact of zero gravity on the developing human brain. These projects will have profound implications for future human colonization (can humans successfully reproduce in space?). These studies will also improve the generation of artificial organs that are used for testing drugs and treatments on Earth. Will better treatments for neurodevelopmental and neurodegenerative conditions that affects millions of people come from research in space?

Read this article:
Why are scientists trying to manufacture organs in space? - Stuff Magazines

Gear up for the change! AgeX Therapeutics Inc. (AGE) has hit the volume of 2356457 – The InvestChronicle

Lets start up with the current stock price of AgeX Therapeutics Inc. (AGE), which is $1.26 to be very precise. The Stock rose vividly during the last session to $1.40 after opening rate of $0.99 while the lowest price it went was recorded $0.94 before closing at $0.96.

Recently in News on June 16, 2020, AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications. AgeX Therapeutics, Inc. (AgeX: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Pluristyx, Inc. (Seattle, WA), an advanced therapy tools and services company serving customers in the rapidly growing fields of regenerative medicine and cellular and gene therapies, today announced they have entered into a Manufacturing, Marketing, and Distribution Agreement through which Pluristyx will undertake these activities on behalf of AgeX with respect to AgeXs research- and clinical-grade ESI brand human embryonic stem cells, sometimes referred to as hESCs. You can read further details here

AgeX Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $2.2400 on 01/02/20, with the lowest value was $0.6660 for the same time period, recorded on 04/21/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, AgeX Therapeutics Inc. shares are logging -59.87% during the 52-week period from high price, and 89.19% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.67 and $3.14.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2356457 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the AgeX Therapeutics Inc. (AGE) recorded performance in the market was -30.77%, having the revenues showcasing 59.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 50.56M, as it employees total of 17 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.8843, with a change in the price was noted +0.1000. In a similar fashion, AgeX Therapeutics Inc. posted a movement of +8.62% for the period of last 100 days, recording 309,646 in trading volumes.

Raw Stochastic average of AgeX Therapeutics Inc. in the period of last 50 days is set at 45.74%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 77.27%. In the last 20 days, the companys Stochastic %K was 68.95% and its Stochastic %D was recorded 58.59%.

Considering, the past performance of AgeX Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -30.77%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -31.89%, alongside a downfall of -55.16% for the period of the last 12 months. The shares increased approximately by 37.45% in the 7-day charts and went down by 55.12% in the period of the last 30 days. Common stock shares were driven by 59.01% during last recorded quarter.

The rest is here:
Gear up for the change! AgeX Therapeutics Inc. (AGE) has hit the volume of 2356457 - The InvestChronicle

Global Stem Cell Therapy Market Report Examines Analysis By Size, Share, Latest Trends, Future Growth, Top Key Players And Forecast To 2027 – Jewish…

The New Report Titled as Stem Cell Therapy Market published by Global Marketers, covers the market landscape and its evolution predictions during the forecast period. The report objectives to provide an overview of global Stem Cell Therapy Market with detailed market segmentation by solution, security type, application and geography. The Stem Cell Therapy Market is anticipated to eyewitness high growth during the forecast period. The report delivers key statistics on the market status of the leading market players and deals key trends and opportunities in the market.

Request For Free Sample Report: @ https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request_sample

This research report also includes profiles of major companies operating in the global market. Some of the prominent players operating in the Global Stem Cell Therapy Market are:

Celgene Corporation Osiris Therapeutics, Inc. Pharmicell Co., Ltd MEDIPOST Co., Ltd. Promethera Biosciences Fibrocell Science, Inc. Holostem Terapie Avanzate S.r.l. Cytori Therapeutics Nuvasive, Inc. RTI Surgical, Inc. Anterogen Co., Ltd. RTI Surgical, Inc

The Stem Cell Therapy Market for the regions covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Regional breakdown has been done based on the current and forthcoming trends in the global Stem Cell Therapy Market along with the discrete application segment across all the projecting region.

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/57925

The Type Coverage in the Market are:

Adult Stem Cells Human Embryonic Induced Pluripotent Stem Cells Very Small Embryonic Like Stem Cells

Market Segment by Applications, covers:

Regenerative Medicine Drug Discovery and Development

Some Major TOC Points:

Chapter 1. Stem Cell Therapy Market Report Overview

Chapter 2. Global Stem Cell Therapy Market Growth Trends

Chapter 3. Market Share by Key Players

Chapter 4. Stem Cell Therapy Market Breakdown Data by Type and Application

Chapter 5. Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Stem Cell Therapy Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Force

Continue for TOC

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#inquiry_before_buying

Key questions Answered in this Stem Cell Therapy Market Report:

What will be the Stem Cell Therapy Market growth rate and value in 2020?

What are the key market predictions?

What is the major factors of driving this sector?

What are the situations to market growth?

Major factors covered in the report:

Global Stem Cell Therapy Market summary

Economic Impact on the Industry

Stem Cell Therapy Market Competition in terms of Manufacturers

Stem Cell Therapy Market Analysis by Application

Marketing Strategy comprehension, Distributors and Traders

Study on Market Research Factors

Table of Content & Report Detail @ https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#table_of_contents

See the rest here:
Global Stem Cell Therapy Market Report Examines Analysis By Size, Share, Latest Trends, Future Growth, Top Key Players And Forecast To 2027 - Jewish...

Differentiation of Human iPS and ES Cells – Scientist Live

AMSBIO has introduced StemFit for Differentiation - a new chemically defined and animal component-free formulation that enables unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells.

The unique chemically defined composition of StemFit for Differentiation minimizes lot-to-lot variation, enabling highly consistent cell differentiation. Free of animal- and human-derived components, StemFit for Differentiation can be used to eliminate the risk of immunogenic contamination.

Applications proven to benefit from StemFit for Differentiation include: lineage-specific (endodermal, mesodermal and ectodermal) differentiation where this new product is used to replace serum-free supplements, as well as spontaneous differentiation of hiPSCs to organoids via embryoid body formation.

Used in combination with StemFit Basic feeder-free medium with iMatrix-511 laminin as extracellular matrix, StemFit for Differentiation enables researchers to undertake clinical applications involving both expansion and differentiation of human Pluripotent Stem Cell-derived cells and tissues.

Supplied as a 5X concentrate, StemFit for Differentiation has been formulated for use with basal cell culture medium (e.g. DMEM, RPMI 1640, DMEM/F12 etc.) and a variety of different induction factors or cytokines (including Activin A and bFGF from AMSBIO).

Continue reading here:
Differentiation of Human iPS and ES Cells - Scientist Live

Clinton Vows to Fund Embryonic Stem Cell Research as …

By Peter J. Smith

WASHINGTON, D.C., October 9, 2007 (LifeSiteNews.com) - Democratic presidential candidate Hillary Rodham Clinton has promised to sign an executive order overturning President Bushs restrictions on federal funding for embryonic stem cell research once she is elected President.

The former First Lady and current junior senator from New York told her audience at the Carnegie Institution for Science that President Bush was waging a "war on science" that hindered the United States from becoming the "innovation nation."

"I will lift the current ban on ethical stem cell research," Clinton said. "The presidents ban on stem cell funding amounts to a ban on hope."

However the US has no actual ban on embryonic stem cell research. Regulations established by the Bush administration in August 2001 prohibit researchers from using federal funds to create new lines of embryonic stem cells, but it does not hinder private companies from funding their work.

"In her rush to attack the president, Hillary Clinton has conveniently forgotten that George W. Bush is the only president who has ever made federal money available for stem cell research," said Republican National Committee spokesman Danny Diaz according to Reuters.

Clintons speech also gave the impression that "ethical" stem cell research was synonymous with embryonic stem cell research, although this premise is hotly contested within the scientific community. A number of stem cell researchers reject on a practical basis any need to drive into ethically dubious territory, since stem cell therapies are continuing to be produced from non-controversial sources (e.g. adult stem cells, umbilical cord blood). On the other hand, the promise of cures from experimentation with embryonic stem cells is filled with more hot air than hope, since the cells derived from the destruction of a human embryo are naturally designed to work in the fast-developing embryonic environment and have been shownto be incompatible and tumor-causing in adult tests.

See related coverage by LifeSiteNews.com

Adult Stem Cell Research: True Potential Sacrificed for Other Possibilities Says Biotech Writer http://www.lifesitenews.com/ldn/2006/jun/06061311.html

UK Researcher: Cord Blood Real Potential for Cures, Not Embryonic Stem Cells - Part 1 http://www.lifesitenews.com/ldn/2006/aug/06081804.html

UK Researcher: Embryonic Stem Cells Have Never Been Used to Treat Anyone and no Plans Exist to do so http://www.lifesitenews.com/ldn/2006/aug/06082401.html

See more here:
Clinton Vows to Fund Embryonic Stem Cell Research as ...

embryonic stem cell NIH Director’s Blog

Posted on September 20th, 2016 by Dr. Francis Collins

Many people probably think of mice as unwanted household pests. But over more than a century, mice have proven to be incredibly valuable in medical research. One of many examples is how studies in mice are now helping researchers understand how mammalian genomes work, including the human genome. Scientists have spent decades inactivating, or knocking out, individual genes in laboratory mice to learn which tissues or organs are affected when a specific gene is out of order, providing valuable clues about its function.

More than a decade ago, NIH initiated a project called KOMPthe Knockout Mouse Project [1]. The goal was to use homologous recombination (exchange of similar or identical DNA) in embryonic stem cells from a standard mouse strain to knock out all of the mouse protein-coding genes. That work has led to wide availability of such cell lines to investigators with interest in specific genes, saving time and money. But its one thing to have a cell line with the gene knocked out, its even more interesting (and challenging) to determine the phenotype, or observable characteristics, of each knockout. To speed up that process in a scientifically rigorous and systematic manner, NIH and other research funding agencies teamed to launch an international research consortium to turn those embryonic stem cells into mice, and ultimately to catalogue the functions of the roughly 20,000 genes that mice and humans share. The consortium has just released an analysis of the phenotypes of the first 1,751 new lines of unique knockout mice with much more to come in the months ahead. This initial work confirms that about a third of all protein-coding genes are essential for live birth, helping to fill in a major gap in our understanding of the genome.

Posted In: Health, Science

Tags: conserved genes, embryonic development, embryonic stem cell, essential genes, genes, genetic conditions, genetics, genomics, homologous recombination, humans, International Mouse Phenotyping Consortium, knockout mice, Knockout Mouse Project, KOMP, miscarriages, mouse, phenotype, stem cells, stillbirths

Posted on July 19th, 2016 by Dr. Francis Collins

Caption: From stem cells to bone. Human bone cell progenitors, derived from stem cells, were injected under the skin of mice and formed mineralized structures containing cartilage (1-2) and bone (3). Credit: Loh KM and Chen A et al., 2016

To help people suffering from a wide array of injuries and degenerative diseases, scientists and bioengineers have long dreamed of creating new joints and organs using human stem cells. A major hurdle on the path to achieving this dream has been finding ways to steer stem cells into differentiating into all of the various types of cells needed to build these replacement parts in a fast, efficient manner.

Now, an NIH-funded team of researchers has reported important progress on this front. The researchers have identified for the first time the precise biochemical signals needed to spur human embryonic stem cells to produce 12 key types of cells, and to do so rapidly. With these biochemical recipes in hand, researchers say they should be able to generate pure populations of replacement cells in a matter of days, rather than the weeks or even months it currently takes. In fact, they have already demonstrated that their high-efficiency approach can be used to produce potentially therapeutic amounts of human bone, cartilage, and heart tissue within a very short time frame.

Posted In: Health, Science

Tags: bioengineering, Bone, cartilage, development, embryonic stem cell, heart cells, human embryonic stem cell, mesoderm, muscle cells, regenerative medicine, replacement tissue, RNA sequencing, scoliosis, stem cell differentiation, stem cells, tissue engineering

Posted on June 2nd, 2015 by Dr. Francis Collins

If youre curious what innovations are coming out of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, take a look at this video shot via a microscope. What at first glance looks like water dripping through pipes is actually a cool new technology for swiftly and efficiently analyzing the gene activity of thousands of individual cells. You might have to watch this video several times and use the pause button to catch all of the steps, but it provides a quick overview of how the Drop-seq microfluidic device works.

First, a nanoliter-sized droplet of lysis buffer containing a bead with a barcoded sequencing primer on its surface slides downward through the straight channel at the top of the screen. At the same time, fluid containing individual cells flows through the curved channels on either side of the bead-bearing channelyou can catch a fleeting glimpse of a tiny cell in the left-hand channel about 5 seconds into the video. The two streams (barcoded-bead primers and cells) feed into a single channel where they mix, pass through an oil flow, and get pinched off into oily drops. Most are empty, but some contain a bead or a celland a few contain both. At the point where the channel takes a hard left, these drops travel over a series of bumps that cause the cell to rupture and release its messenger RNAan indicator of what genes are active in the cell. The mRNAs are captured by the primer on the bead from which, after the drops are broken, they can be transcribed, amplified, and sequenced to produce STAMPS (single-cell transcriptomes attached to microparticles). Because each bead contains its own unique barcode that enables swift identification of the transcriptomes of individual cells, this process can be done simultaneously on thousands of cells in a single reaction.

Posted In: Health, Science, Video

Tags: BRAIN Initiative, Drop-seq, embryonic stem cell, genomics, inDrop, neurology, retina, single cell analysis, technology, transciptome

Here is the original post:
embryonic stem cell NIH Director's Blog

Global Cellular Reprogramming Tools Market: Recent Industry Trends and Projected Industry Growth, 2019 2025 – Jewish Life News

Global Cellular Reprogramming Tools Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The recent published research report sheds light on critical aspects of the global Global Cellular Reprogramming Tools market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Global Cellular Reprogramming Tools market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Global Cellular Reprogramming Tools market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2696613&source=atm

The recent published study includes information on key segmentation of the global Global Cellular Reprogramming Tools market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Global Cellular Reprogramming Tools market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Global Cellular Reprogramming Tools market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Global Cellular Reprogramming Tools Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2696613&source=atm

segment by Type, the product can be split into Adult Stem Cells Human Embryonic Stem Cells Induced Pluripotent Stem Cells Other Market segment by Application, split into Drug Development Regenerative Medicine Toxicity Test Academic Research Other

Market segment by Regions/Countries, this report covers North America Europe China Japan Southeast Asia India Central & South America

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2696613&licType=S&source=atm

Some of the Major Highlights of TOC covers in Global Cellular Reprogramming Tools Market Report:

Chapter 1: Methodology & Scope of Global Cellular Reprogramming Tools Market

Chapter 2: Executive Summary of Global Cellular Reprogramming Tools Market

Chapter 3: Global Cellular Reprogramming Tools Industry Insights

Chapter 4: Global Cellular Reprogramming Tools Market, By Region

Chapter 5: Company Profile

And Continue

See the original post:
Global Cellular Reprogramming Tools Market: Recent Industry Trends and Projected Industry Growth, 2019 2025 - Jewish Life News

COVID-19 UPDATE : Global Human Embryonic Stem Cell Market 2020 Comprehensive Study with Arizona Board of Regents, STEMCELL Technologies Inc, Cellular…

The Global Human Embryonic Stem Cell Market report demonstrates supportive data related to the dominant players in the market such as product offerings, revenue, segmentation, and business synopsis. The report gives helpful insights which assist while launching a new product. This global market research report has complete overview of the market, covering various aspects such as product definition, segmentation based on various parameters, and the prevailing vendor landscape. Moreover, in the Global Human Embryonic Stem Cell Market report, the key product categories are also included. The report also analyses the emerging trends along with major drivers, challenges and opportunities in the Global Human Embryonic Stem Cell Market.

The Global Human Embryonic Stem Cell Market study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness. To understand the competitive landscape in the market, an analysis of Porters five forces model for the market has also been included. Furthermore, businesses can decide upon the strategies about the product, customer, key player, sales, promotion or marketing by acquiring a detailed analysis of competitive markets. The Global Human Embryonic Stem Cell Market report is a synopsis about how is the market status right now and how will it be in the forecast years for industry.

Human embryonic stem cell market estimated to register a healthy CAGR of 10.5% in the forecast period of 2019 to 2026. The imminent market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026. The growth of the market can be attributed to the increase in tissue engineering process.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-human-embryonic-stem-cell-market

Key Market Competitors:

Some of the major companies functioning in global human embryonic stem cell market are Arizona Board of Regents, STEMCELL Technologies Inc, Cellular Engineering Technologies, CellGenix GmbH, PromoCell GmbH, Lonza, Kite Pharma, Takeda Pharmaceutical Company Limited, BrainStorm Cell Limited., CELGENE CORPORATION, Osiris Therapeutics,Inc, U.S. Stem Cell, Inc, Waisman Biomanufacturing, Caladrius, Pfizer Inc., Thermo Fisher Scientific, Merck KGaA, Novo Nordisk A/S, Johnson & Johnson Services, Inc and SA Biosciences Corporation among others.

Global Human Embryonic Stem Cell Market By Type (Totipotent Stem Cells, Pluripotent Stem Cells, Unipotent Stem Cells), Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, Toxicology Testing), End User (Research, Clinical Trials, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

Key Developments in the Market:

In January 2019, STEMCELL Technologies, launched mTeSR Plus, a Next-generation culture system for human embryo system and IPS cell maintenance. This launch will able to promote more consistent cell culture environment through sustained medium pH and stabilized components In January, 2018 Mayo Foundation for Medical Education and Research, got approval on the tool named as automated bioreactor. This tool can manufacture the stem cells, in billions within a day. This will allow the company to harvest the cell from bone marrow, this will allow the treatment of patients when their own cell is not in use, which will allow the Mayo Clinic to accelerate its existing studies using stem cells

Market Definition: Global Human Embryonic Stem Cell Market

Human embryonic stem cell is pluripotent stem cells, derivative of inner cell of blastocyst from inner cell mass of embryo. Embryonic stem cell gives rise to somatic cells in embryo. This is a useful tool to understand the difficult process mechanism involved in growth of specialized cells and establishment of organ structures, which are alternative to cancer therapy.

Market Drivers

Increase prevalence of cardiac and malignant diseases is driving the market growth Growing R&D investments and research initiatives which will propel the market in the forecast period High requirement for regenerative medicines is acting as a catalyst for growth of the market Support from government in funding and regulation can also boost the market growth

Market Restraints

Costly procedures and regulatory complications is acting as a restraint for the market growth Strict regulatory guidelines is hindering the growth of the market Ethical and policy concern may hamper the market in the forecast period

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

Table of Contents-Snapshot Executive Summary Chapter 1 Industry Overview Chapter 2 Industry Competition by Manufacturers Chapter 3 Industry Production Market Share by Regions Chapter 4 Industry Consumption by Regions Chapter 5 Industry Production, Revenue, Price Trend by Type Chapter 6 Industry Analysis by Applications Chapter 7 Company Profiles and Key Figures in Industry Business Chapter 8 Industry Manufacturing Cost Analysis Chapter 9 Marketing Channel, Distributors and Customers Chapter 10 Market Dynamics Chapter 11 Industry Forecast Chapter 12 Research Findings and Conclusion Chapter 13 Methodology and Data Source.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-human-embryonic-stem-cell-market

The current trend pertaining to the demand supply and sales together with the recent developments have been given here to provide an exhaustive picture of this market. It also allows voluntarily accessible affordable reports of the research that is the end result of the personalized research carried by the internal team of professionals.

To comprehend Global Human Embryonic Stem Cell market dynamics in the world mainly, the worldwide Human Embryonic Stem Cell market is analyzed across major global regions.

North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Segmentation: Global Human Embryonic Stem Cell Market

By Type

Totipotent Stem Cells Pluripotent Stem Cells Unipotent Stem Cells

By Application

Regenerative Medicine Stem Cell Biology Research Tissue Engineering Toxicology Testing

By End User

Research Clinical Trials Others

Reasons to Purchase this Report

Current and future of global human embryonic stem cell market outlook in the developed and emerging markets The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period Regions/Countries that are expected to witness the fastest growth rates during the forecast period The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at country level All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

View original post here:
COVID-19 UPDATE : Global Human Embryonic Stem Cell Market 2020 Comprehensive Study with Arizona Board of Regents, STEMCELL Technologies Inc, Cellular...

AMSBIO Introduces StemFit for Differentiation of Human IPS and ES Cells – Technology Networks

AMSBIO has introduced StemFit for Differentiation a new chemically defined and animal component-free formulation that aims to enable unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells.

The unique chemically defined composition of StemFit for Differentiation minimizes lot-to-lot variation, enabling highly consistent cell differentiation. Free of animal- and human-derived components, StemFit for Differentiation can be used to eliminate the risk of immunogenic contamination.

Applications proven to benefit from StemFit for Differentiation include: lineage-specific (endodermal, mesodermal and ectodermal) differentiation where this new product is used to replace serum-free supplements, as well as spontaneous differentiation of hiPSCs to organoids via embryoid body formation.

Used in combination with StemFit Basic feeder-free medium with iMatrix-511 laminin as extracellular matrix, StemFit for Differentiation enables researchers to undertake clinical applications involving both expansion and differentiation of human Pluripotent Stem Cell-derived cells and tissues.

Supplied as a 5X concentrate, StemFit for Differentiation has been formulated for use with basal cell culture medium (e.g. DMEM, RPMI 1640, DMEM/F12 etc.) and a variety of different induction factors or cytokines (including Activin A and bFGF from AMSBIO).

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

Read more here:
AMSBIO Introduces StemFit for Differentiation of Human IPS and ES Cells - Technology Networks